Table 3 Perinatal outcomes in Meis et al. (2003, MFMU) vs. Blackwell et al. (2019, PROLONG).
| Outcome | MFMU | PROLONG | ||||
|---|---|---|---|---|---|---|
| 17-OHPC (%) | Placebo (%) | RR (95% CI) | 17-OHPC (%) | Placebo (%) | RR (95% CI) | |
| MFMU: Maternal-Fetal Medicine Units, PROLONG: Progestinʼs Role in Optimizing Neonatal Gestational Length, 17-OHPC: 17-hydroxyprogesterone caproate, GW: weeks of gestation, BPD: bronchopulmonary dysplasia, RDS: respiratory distress syndrome, NEC: necrotizing enterocolitis, IVH: intraventricular hemorrhage. Data are presented as a percentage (%) or as relative risk with 95% confidence intervals. bold = statistical significance | ||||||
| Birth < 37 GW | 36.3 | 54.9 | 0.66 (0.54 – 0.81) | 23.1 | 21.9 | 1.06 (0.88 – 1.28) |
|
29.4 | 45.1 | 0.65 (0.51 – 0.83) | 18.8 | 17.1 | 1.10 (0.88 – 1.36) |
|
6.9 | 9.8 | 0.70 (0.37 – 1.32) | 4.1 | 4.5 | 0.91 (0.57 – 1.46) |
| Birth < 35 GW | 20.6 | 30.7 | 0.67 (0.48 – 0.93) | 11.0 | 11.5 | 0.95 (0.71 – 1.26) |
| Birth < 32 GW | 11.4 | 19.6 | 0.58 (0.37 – 0.91) | 4.8 | 5.2 | 0.92 (0.60 – 1.42) |
| Miscarriage < 20 GW | 1.6 | 0 | NA | 0.5 | 1.3 | 0.28 (0.08 – 0.94) |
| Antenatal corticosteroids | 17.8 | 19.7 | 0.91 (0.60 – 1.35) | 9.3 | 10.6 | 0.88 (0.65 – 1.20) |
| Tocolytic therapy | 17.3 | 15.9 | 1.09 (0.70 – 1.69) | 11.9 | 10.9 | 1.09 (0.82 – 1.44) |
| BPD | 1.3 | 3.3 | 0.40 (0.11 – 1.46) | 0.5 | 0.2 | 3.02 (0.38 – 24.1) |
| RDS | 9.5 | 15.1 | 0.63 (0.38 – 1.05) | 4.9 | 4.7 | 1.06 (0.67 – 1.68) |
| NEC | 0 | 2.6 | NA | 0.2 | 0.4 | 0.5 (0.07 – 3.40) |
| Chorioamnionitis | 3.6 | 3.3 | 1.09 (0.39 – 3.09) | 0.8 | 0.3 | 2.24 (0.48 – 10.41) |
| Retinopathy | 1.6 | 3.3 | 0.50 (0.15 – 1.70) | 0.5 | 1.3 | 0.37 (0.12 – 1.16) |
| IVH grade 3 or 4 | 0.7 | 0 | NA | 0.2 | 0.2 | 0.99 (0.09 – 10.52) |
| Confirmed sepsis | 3.0 | 2.6 | 1.12 (0.35 – 3.58) | 0.5 | 0.5 | 0.84 (0.20 – 3.56) |